Background
A meta-analysis of chronic pain in the UK suggested prevalence's of 35e51% for all severities of chronic pain and 10e14% for severe chronic pain. The prevalence in those aged 18e39 yr was up to 30%, chronic pain being more common in females than in males. 1 Although the understanding of the mechanisms of pain has improved, treatment successes tend to be patient-specific. This is most likely because of the complex aetiology of chronic pain and the differences in assessment of a successful outcome from the perspectives of the patient and the doctor. This high prevalence of chronic pain in conjunction with the limited number of successful treatment options has contributed to the corresponding increase in opioid prescribing.
The acute and medium-term adverse effects of opioids are well known. Opioids alleviate pain in the short term, but they can cause sedation, dizziness, nausea, vomiting, constipation, respiratory depression, and tolerance. These effects are dosedependent and reversible on withdrawal of the opioid medication. The impact on society of long-term opioid therapy is also being seen, with increases in criminal behaviour.
Substance use disorder
Substance use disorder is defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Hugh Gallagher FCARCSI DABPM DPM FFPMCAI is a consultant in anaesthesia and pain medicine at St Vincent's University Hospital, Dublin. He is incoming Vice Dean of the Faculty of Pain Medicine of the College of Anaesthetists of Ireland.
Deborah Galvin FCAI DPM is a senior trainee in pain medicine at St Vincent's University Hospital.
Key points
2% of Europeans have an opioid use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria. There is little evidence for using opioids as therapy for chronic, non-cancer pain beyond 16 weeks' duration. Guidelines are available describing multimodal approaches to chronic pain management; advice on opioid trials; riskebenefit analysis; identification of risk factors for harm or misuse; and treatment of addiction and overdose. Opioids may be indicated for chronic painful diabetic neuropathy, and elderly patients with osteoarthritis of the back and knee. It is estimated that approximately 22.8 million Europeans use prescription opioid medication with an estimated 445,000 (2%) having an opioid use disorder. 3 The diagnosis of an opioid use disorder in a patient with chronic pain is very difficult, with some studies suggesting a prevalence as high as 20e25%. 4 Despite the widespread prescribing of opioids for chronic pain, there is a lack of evidence of improvement in chronic pain when a patient receives long-term opioid therapy. Placebo-controlled trials comparing opioid therapy with no therapy, or non-opioid therapy lasting up to 12 weeks have been performed. 5 However, the vast majority of trials for opioid therapy are for 6 weeks or less. Most of the positive published data appear to be in the patients with painful diabetic neuropathy. Long-term studies of the effectiveness of opioid use greater than 12 weeks are lacking, and more research is needed into long-term opioid therapy for chronic pain and its subsequent effects. There is also a lack of evidence regarding the effectiveness of opioid therapy in improving physical function in patients with chronic pain. Many observational trials have been performed but have drawn no definitive conclusions about functional improvement. This appears to be mainly because of significant dissatisfaction amongst patients caused by inadequate pain relief, but also the heterogeneity of the chronic pain conditions studied and patients' difficulties with functional evaluation.
Observational trials have also shown that long-term opioid use is associated with an increased risk of accidental overdose, opioid abuse, dependence, fractures (particularly hip and upper limb), and myocardial infarction. 6 Other effects of long-term opioid therapy have been described in recent years. These include hypogonadism, osteoporosis, immune suppression, cognitive impairment, and opioid-induced hyperalgesia (OIH). The risks of addiction and overdose remain a problem, although addiction may not be the key risk in longterm opioid users. Continued use of opioids despite harm is a major concern. A difficulty arises when a patient has a failed opioid trial but remains on opioids with the associated risk outweighing any benefit. The lack of an exit strategy for these patients remains a major issue and encourages the focus of treatment to shift to other options involved in the multidisciplinary approach. Also, the risk of drug diversion is a major public health and societal concern that results in increased healthcare costs, and alteration and derailment of treatment plans.
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Opioid-induced hyperalgesia
OIH is defined as a decrease in the nociceptive threshold caused by exposure to opioids. It can be mistaken for tolerance and can lead to dose escalation of the prescribed opioid, which can worsen the patient's pain through pronociceptive mechanisms. It is acknowledged that making the distinction between OIH and tolerance can be very difficult. The exact mechanism and location of OIH is uncertain, but five mechanisms have been suggested: changes in the central glutaminergic system mediated by activation of N-methyl-Daspartate (NMDA) receptors; increased spinal dynorphins; activation of descending pathways; genetic mechanisms; and decreased neurotransmitter reuptake and enhanced nociceptive responses. 8 The opioid 'epidemic'
The Surgeon General in the USA introduced a campaign in 2016 called 'Turn the Tide Rx'. This campaign is aimed at primary care practitioners and invites them to take a pledge to help end the opioid crisis. The need for such a campaign was indicated by the large increase in the prescription of opioids for chronic pain conditions, outside of end-of-life and cancer care treatment programmes, and also by the rapid increase in numbers of fatalities caused by accidental overdose over the past 20 yr; opioids were involved in 63% of drug overdoses in the USA in 2015. Half of these overdoses involved a prescribed opioid. The prescription of opioids in the USA quadrupled between 1999 and 2010. The number of opioid-associated deaths since 1999 has also quadrupled. 9 In 2012, 259 million prescriptions were written for opioids medication in the USA, almost one prescription per person. The rate of prescriptions per 100 persons varied from 72 to 80 in the years 2006e2015. The amount of opioid prescriptions has increased 3-fold from between 1999 and 2015 with a peak in 2010 in the US. Morphine milligram equivalents (MME) per day is a tool used to assign a value to opioids to represent their relative potencies. The aim of this tool is to allow conversion from one opioid to another. However, there are multiple issues surrounding MME conversion, and various conversion tables exist. The lack of an internationally accepted opioid conversion method may result in underdosing or accidental overdose when rotating from one opioid to another. Opioids display different pharmacokinetics at different doses, for example methadone accumulates when the dosing interval is less than the elimination half-life. The half-life of methadone can vary from 8 to 59 h with large inter-individual variability. In comparison, the analgesic effect of methadone is 6e8 h, resulting in possible accumulation if the dosing interval is too frequent. Respiratory depression and cardiac arrest may result.
The MME per day per capita in the USA was 670 mg in 2011. In Europe, peak opioid consumption occurred in 2010 with a daily MME per capita of 170 mg. The UK experienced a peak in MME of just greater than 800 mg per capita in 2010; in Germany the peak was 600 mg MME per capita in 2013; in France an MME of just below 250 mg per capita was recorded in 2013. Opioid consumption in Australia has also increased, with an MME of 500 mg per capita in 2014. Corresponding figures for Ireland were just below 350 mg MME per capita in 2012 and just above 350 mg MME per capita in 2014. 10 Other European statistics are similar, with 5e7% of all patients entering drug treatment programmes in Europe reporting prescription opioids as their primary drug, and around 10 million people receive regular prescriptions for opioid analgesics. There has been a 400% increase in prescriptions for opioids in the past 10 yr. The number of opioid prescriptions in England increased 5-fold (from 3 million to 15 million prescriptions) between 1991 and 2009. 11 In the same study, tramadol was prescribed almost twice as frequently as any other opioid. Opioids (including heroin) were associated with 64% of drug-related deaths in the UK in 2015 (Table 1) . 12 A retrospective cohort study published in 2016 showed that 91% of those who previously overdosed on opioids were represcribed opioids; 7% of these patients had a repeat overdose. 13 Trends in the developing world are 20 yr behind the USA and Europe, with opioid prescribing for chronic pain on the increase.
International guidelines
In response to the international crisis concerning opioid prescriptions, many countries have produced guidelines and advisory documents on the approach to chronic pain management and the safe prescribing of opioids for non-cancer pain, as it is recognised that only a small group of chronic pain patients will benefit from chronic opioid therapy. The US Center for Disease Control and Prevention (CDC) issued guidelines in March 2016 regarding initiation or continuation on opioid medications.
14 These guidelines are condensed in a pocket card for opioid prescribing, summarised in Table 2 . 15 The Faculty of Pain Medicine (FPM) in the UK launched a resource called 'Opioids Aware' for both patients and healthcare professionals to promote the safer prescribing of opioids. It aims to reinforce prescribing by the application of best practice: ensuring understanding of the condition, the patient and their context, and understanding the clinical use of the drug. 16 The FPM resource provides information on opioids and the law, opioid prescribing guidelines, importance of accurate record-keeping, the importance of patient assessment before commencing opioids to identify potential for addiction or tolerance, long-term opioids and their adverse effects, how to perform an opioid trial, opioid equivalents, and information on stopping opioid therapy. The resource also provides information for patients commencing opioid therapy, including information on chronic pain, the options available to them, and a list of frequently asked questions and answers.
The importance of clinical record keeping is highlighted in the FPM guideline. Records should include: 
Before prescribing
Assess pain and function. Consider if non-opioid therapies are appropriate.
Talk to patients about treatment plan. Evaluate risk of harm or misuse.
When you prescribe
Start low and go slow. Commence immediate release opioids for the shortest therapeutic duration. Arrange frequent follow-up for patients on 50 MME day À1 or more or those who may have risk factors.
After initiation of opioid therapy
Regularly assess the benefits. Tailor and taper the dose. Continue therapy after a successful trial period.
Treating overdose and addiction
Regularly screen for opioid use disorder. Considering offering naloxone for at-risk patients. MME, morphine milligram equivalence.
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(iv) A clear account of how, when, and in what circumstances the dose of drug should be adjusted. This should also be given to the patient.
It is very important to discuss and agree with the patient when opioid therapy should be discontinued. Ideally, the patient should bring someone with them for the consultation before starting opioids. This will allow for discussion around acute illness and reiterate the awareness needed if the patient becomes acutely unwell but remains taking the same dose of opioids. Education about naloxone, in the case of a suspected opioid overdose, can also be given.
Use of guidelines
The use of guidelines without evidence-based research can have its own limitations. This is seen in the topic of longterm opioid therapy. No studies beyond 12 weeks of treatment with opioids exist, which means the guidelines offered are based on expert opinion and clinical experience. The presence of guidelines means the decision to refer from a family doctor to a pain medicine physician may become less clear as rigidly adhering to the guidelines may still pose a risk to a patient regardless of how 'low' their opioid dose is. The need for continuous assessment of riskebenefit is more important than strictly adhering to the guidelines and not recognising the risk associated with any opioid dose.
The dose of 90 mg MME day À1 is simply a level above which the risk has been measured and deemed high. A risk exists at all doses, and this risk increases as the dose increases. Furthermore, the guidelines cannot take into consideration any pre-existing conditions such as old age, respiratory diseases, or pre-existing substance use disorders.
Overdose prevention
The risk of mortality is present at all doses and increases as the dose increases. Simultaneous consumption of other psychoactive medications may increase overdose risk. The best method to prevent overdose in these patients is to decrease the amount of opioid consumed to the minimal effective dose, or to wean patients from opioids entirely. However, a significant proportion of opioid-dependent patients will struggle with weaning, and it is this group of individuals who are at an increased risk of accidental overdose. Methods to decrease the risk of overdose include improving opioid prescribing to prevent abuse and early recognition of addiction and timely referral to addiction services. Acute illness can increase the effective potency of opioids. Patients and their families need to be made aware of this when initiating therapy and frequently during follow-up. The co-prescribing of naloxone to patients at high risk of overdose is a possible harmreduction strategy and should be considered for patients consuming opioids or with additional risk because of significant pre-existing illnesses. Naloxone has essentially no pharmacological effect if administered to a patient who has not taken an opioid. Patients can be prescribed naloxone, and family members should be instructed both in the assessment of suspected opioid overdose and in the administration of naloxone. The usual route in overdose is i.v., but the intranasal route has proved to be effective in a community setting, where it will most likely be administered by nonmedically trained individuals. 17 
Beneficial effects of opioids
Chronic opioid therapy has proved beneficial to certain groups of patients. Use of tapentadol (mu-opioid agonist and noradrenaline re-uptake inhibitor) has been shown to be associated with a clinically significant reduction in pain intensity over a 3-week period in patients with chronic, painful diabetic neuropathy (100e250 mg twice per day). This reduction in pain intensity was sustained for a further 9 weeks. 18 The most common adverse events were gastrointestinal, which caused 10% of patients to discontinue the medication. Use of opioids including tapentadol in patients older than 75 yr with back pain and knee pain caused by osteoarthritis has also been studied. 19 Differences in improvements in pain intensity are not statistically significant, but tapentadol appears to have a better gastrointestinal adverse effect profile. 20 Psychological techniques and interventional procedures are limited in these patients, and so medications are mainstay of treatment. A reduction in treatment-associated adverse effects is desirable, but it is unknown whether stopping opioids reverses these.
Conclusion
Despite the lack of evidence for opioids in chronic noncancer pain, prescribing has increased substantially over the past 20 yr. Both the clinician and the patient have responsibilities regarding the safe prescribing and use of opioids for chronic non-cancer pain. The challenges facing clinicians are to prevent further increases in rates of opioid prescribing and, after a successful opioid trial, to ensure those who benefit are prescribed opioids by an appropriately trained professional.
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